Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose pharmacokinetics of Aliskiren and Atenolol alone and in combination in healthy subjects
2005-001252-21Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of aliskiren and atenolol in hypertension (HTN) (3 arms), sponsored by Novartis. Primary endpoint: Primary pharmacokinetic assessment of Aliskiren. Started May 2006; status: completed.
02
Drugs
aliskirenatenolol
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2005-001252-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001252-21.